Centre Francois Baclesse

Caen, Calvados 14076

1 studies enrolling now · 6 studies all time

What they study most

Advanced Non-Small-Cell Lung Cancer, Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC), Breast Cancer, EGFR P-Loop and Alpha C-Helix Compressing, EGFR PACC, EGFR Uncommon Mutations, Early Breast Cancer, HER2 Amplification, HER2 Gene Mutation, HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, Lymphoma

Studies at this site

• Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations — Recruiting now
• A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) — Running, not enrolling
• TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations — Running, not enrolling
• A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202) — Completed
• ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer — Running, not enrolling
• Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer — Completed